H-Thr(Trt)OH | 133179-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: H-Thr(Trt)OH
• 英文别名: trityl ether of L-threonine；(2S,3R)-2-amino-3-trityloxybutanoic acid
• CAS: 133179-99-4
• 化学式: C₂₃H₂₃NO₃
• 分子量: 361.441
• InChiKey: NIIMOYXLKQFSST-UTKZUKDTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  氯甲酸-9-芴基甲酯 、 H-Thr(Trt)OH 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 Fmoc-O-三苯甲基-L-苏氨酸
  参考文献：
  名称：

  N-Fmoc-O-Trt-hydroxyaminosäurenzur“固相”合成冯肽

  摘要：

  The preparation of the N-Fmoc-O-Trt derivatives of serine, threonine and tyrosine is described. Their usefulness in peptide synthesis has been determined in the successful solid phase preparation of the partially protected ACTH (fragment 1-10) and peptide T 12. The latter, having six hydroxy amino acid side chains protected with Trt groups, can be quantitatively cleaved from the applied 2-chlorotrityl resin with simultaneous side chain deprotection.

  DOI：

  10.1016/s0040-4039(00)79471-8
• 作为产物：
  描述：

  三苯基氯甲烷 、 Trt-Thr-OH * Et3N 在 4-二甲氨基吡啶 、 2,2,2-三氟乙醇 、 溶剂黄146 、 三乙胺 作用下， 生成 H-Thr(Trt)OH
  参考文献：
  名称：

  N-Fmoc-O-Trt-hydroxyaminosäurenzur“固相”合成冯肽

  摘要：

  The preparation of the N-Fmoc-O-Trt derivatives of serine, threonine and tyrosine is described. Their usefulness in peptide synthesis has been determined in the successful solid phase preparation of the partially protected ACTH (fragment 1-10) and peptide T 12. The latter, having six hydroxy amino acid side chains protected with Trt groups, can be quantitatively cleaved from the applied 2-chlorotrityl resin with simultaneous side chain deprotection.

  DOI：

  10.1016/s0040-4039(00)79471-8

文献信息

• [EN] SACCHARIDE FUNCTIONALISED CARBABORANE CONJUGATES OF HUMAN PEPTIDE Y<br/>[FR] CONJUGUÉS DE CARBABORANE FONCTIONNALISÉS PAR DES SACCHARIDES DU PEPTIDE Y HUMAIN
  申请人：UNIV LEIPZIG

  公开号：WO2019115609A1

  公开（公告）日：2019-06-20

  The present invention covers peptidic human Y1 receptor agonist - saccharide functionalised carbaborane conjugate compounds of general formula (I): X5PSX1PX6FPGX7X8X9PX10X11X12X13X2X14YYX3X15X16X17X4YINLITRPRY-NH2, in which F, G, I, L, N, P, R, S, T, Y, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, and X17 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.